Literature DB >> 22057274

Plasticity in interactions of fibroblast growth factor 1 (FGF1) N terminus with FGF receptors underlies promiscuity of FGF1.

Andrew Beenken1, Anna V Eliseenkova, Omar A Ibrahimi, Shaun K Olsen, Moosa Mohammadi.   

Abstract

Tissue-specific alternative splicing in the second half of Ig-like domain 3 (D3) of fibroblast growth factor receptors 1-3 (FGFR1 to -3) generates epithelial FGFR1b-FGFR3b and mesenchymal FGFR1c-FGFR3c splice isoforms. This splicing event establishes a selectivity filter to restrict the ligand binding specificity of FGFRb and FGFRc isoforms to mesenchymally and epithelially derived fibroblast growth factors (FGFs), respectively. FGF1 is termed the "universal FGFR ligand" because it overrides this specificity barrier. To elucidate the molecular basis for FGF1 cross-reactivity with the "b" and "c" splice isoforms of FGFRs, we determined the first crystal structure of FGF1 in complex with an FGFRb isoform, FGFR2b, at 2.1 Å resolution. Comparison of the FGF1-FGFR2b structure with the three previously published FGF1-FGFRc structures reveals that plasticity in the interactions of the N-terminal region of FGF1 with FGFR D3 is the main determinant of FGF1 cross-reactivity with both isoforms of FGFRs. In support of our structural data, we demonstrate that substitution of three N-terminal residues (Gly-19, His-25, and Phe-26) of FGF2 (a ligand that does not bind FGFR2b) for the corresponding residues of FGF1 (Phe-16, Asn-22, and Tyr-23) enables the FGF2 triple mutant to bind and activate FGFR2b. These findings taken together with our previous structural data on receptor binding specificity of FGF2, FGF8, and FGF10 conclusively show that sequence divergence at the N termini of FGFs is the primary regulator of the receptor binding specificity and promiscuity of FGFs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057274      PMCID: PMC3270963          DOI: 10.1074/jbc.M111.275891

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

1.  Mapping ligand binding domains in chimeric fibroblast growth factor receptor molecules. Multiple regions determine ligand binding specificity.

Authors:  A Chellaiah; W Yuan; M Chellaiah; D M Ornitz
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

2.  Structural interactions of fibroblast growth factor receptor with its ligands.

Authors:  D J Stauber; A D DiGabriele; W A Hendrickson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways.

Authors:  Y R Hadari; N Gotoh; H Kouhara; I Lax; J Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

4.  Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.

Authors:  A N Plotnikov; S R Hubbard; J Schlessinger; M Mohammadi
Journal:  Cell       Date:  2000-05-12       Impact factor: 41.582

5.  Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins.

Authors:  S H Ong; Y R Hadari; N Gotoh; G R Guy; J Schlessinger; I Lax
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

6.  Structural basis for FGF receptor dimerization and activation.

Authors:  A N Plotnikov; J Schlessinger; S R Hubbard; M Mohammadi
Journal:  Cell       Date:  1999-09-03       Impact factor: 41.582

7.  Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome.

Authors:  O A Ibrahimi; A V Eliseenkova; A N Plotnikov; K Yu; D M Ornitz; M Mohammadi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

8.  Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity.

Authors:  Elizabeth Tomlinson; Ling Fu; Linu John; Bruce Hultgren; Xiaojian Huang; Mark Renz; Jean Philippe Stephan; Saio Ping Tsai; Lyn Powell-Braxton; Dorothy French; Timothy A Stewart
Journal:  Endocrinology       Date:  2002-05       Impact factor: 4.736

9.  Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization.

Authors:  J Schlessinger; A N Plotnikov; O A Ibrahimi; A V Eliseenkova; B K Yeh; A Yayon; R J Linhardt; M Mohammadi
Journal:  Mol Cell       Date:  2000-09       Impact factor: 17.970

10.  Phosphatidylinositol-3 kinase acts in parallel to the ERK MAP kinase in the FGF pathway during Xenopus mesoderm induction.

Authors:  R Carballada; H Yasuo; P Lemaire
Journal:  Development       Date:  2001-01       Impact factor: 6.868

View more
  19 in total

1.  An S116R Phosphorylation Site Mutation in Human Fibroblast Growth Factor-1 Differentially Affects Mitogenic and Glucose-Lowering Activities.

Authors:  Xue Xia; Ozan S Kumru; Sachiko I Blaber; C Russell Middaugh; Ling Li; David M Ornitz; Jae Myoung Suh; Annette R Atkins; Michael Downes; Ronald M Evans; Connie A Tenorio; Ewa Bienkiewicz; Michael Blaber
Journal:  J Pharm Sci       Date:  2016-10-20       Impact factor: 3.534

Review 2.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

3.  Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory Homodimerization.

Authors:  Yang Liu; Jinghong Ma; Andrew Beenken; Lakshmi Srinivasan; Anna V Eliseenkova; Moosa Mohammadi
Journal:  Structure       Date:  2017-07-27       Impact factor: 5.006

4.  Engineering a Cysteine-Free Form of Human Fibroblast Growth Factor-1 for "Second Generation" Therapeutic Application.

Authors:  Xue Xia; Ozan S Kumru; Sachiko I Blaber; C Russell Middaugh; Ling Li; David M Ornitz; Mason A Sutherland; Connie A Tenorio; Michael Blaber
Journal:  J Pharm Sci       Date:  2016-04       Impact factor: 3.534

5.  Probing the role of proline -135 on the structure, stability, and cell proliferation activity of human acidic fibroblast growth factor.

Authors:  Julie Eberle Davis; Arwa Alghanmi; Ravi Kumar Gundampati; Srinivas Jayanthi; Ellen Fields; Monica Armstrong; Vanessa Weidling; Varun Shah; Shilpi Agrawal; Bhanu Prasanth Koppolu; David A Zaharoff; Thallapuranam Krishnaswamy Suresh Kumar
Journal:  Arch Biochem Biophys       Date:  2018-07-19       Impact factor: 4.013

6.  Divergent requirements for fibroblast growth factor signaling in zebrafish maxillary barbel and caudal fin regeneration.

Authors:  Robert J Duszynski; Jacek Topczewski; Elizabeth E LeClair
Journal:  Dev Growth Differ       Date:  2013-01-28       Impact factor: 2.053

7.  Cooperative heparin-mediated oligomerization of fibroblast growth factor-1 (FGF1) precedes recruitment of FGFR2 to ternary complexes.

Authors:  Alan Brown; Christopher J Robinson; John T Gallagher; Tom L Blundell
Journal:  Biophys J       Date:  2013-04-16       Impact factor: 4.033

Review 8.  Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology.

Authors:  Artur A Belov; Moosa Mohammadi
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-06-01       Impact factor: 10.005

9.  Investigating the dynamics and polyanion binding sites of fibroblast growth factor-1 using hydrogen-deuterium exchange mass spectrometry.

Authors:  Siva K Angalakurthi; Connie A Tenorio; Michael Blaber; Charles Russell Middaugh
Journal:  Protein Sci       Date:  2018-05-03       Impact factor: 6.725

10.  Inclusion of the orientational entropic effect and low-resolution experimental information for protein-protein docking in Critical Assessment of PRedicted Interactions (CAPRI).

Authors:  Sheng-You Huang; Chengfei Yan; Sam Z Grinter; Shan Chang; Lin Jiang; Xiaoqin Zou
Journal:  Proteins       Date:  2013-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.